These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1195 related items for PubMed ID: 7962337

  • 21. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

  • 22. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
    Lundin P, Edén Engström B, Karlsson FA, Burman P.
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
    [Abstract] [Full Text] [Related]

  • 23. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K.
    Endokrynol Pol; 2010 Apr; 61(2):178-81. PubMed ID: 20464704
    [Abstract] [Full Text] [Related]

  • 24. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 25. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 26. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
    Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.
    Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
    [Abstract] [Full Text] [Related]

  • 27. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
    Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, Hagen C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
    [Abstract] [Full Text] [Related]

  • 28. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas.
    Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F, Epelbaum J.
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1577-83. PubMed ID: 7903312
    [Abstract] [Full Text] [Related]

  • 29. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
    Abe T, Lüdecke DK.
    Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
    [Abstract] [Full Text] [Related]

  • 30. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P.
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [Abstract] [Full Text] [Related]

  • 31. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
    Colao A, Merola B, Ferone D, Marzullo P, Cerbone G, Longobardi S, Di Somma C, Lombardi G.
    Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
    [Abstract] [Full Text] [Related]

  • 32. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

  • 33. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
    [Abstract] [Full Text] [Related]

  • 34. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

  • 35. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S.
    Endocr J; 2015 Dec; 62(1):21-7. PubMed ID: 25273395
    [Abstract] [Full Text] [Related]

  • 36. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 37. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 38. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
    Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G.
    Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
    [Abstract] [Full Text] [Related]

  • 39. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
    Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.